Description
Glifo-M 12.5 mg/500 mg is an oral antidiabetic medication manufactured by ACME Laboratories Ltd., combining two active ingredients: Empagliflozin and Metformin Hydrochloride. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces glucose reabsorption in the kidneys, leading to increased glucose excretion and lower blood glucose levels. Metformin, a biguanide, decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity. This combination is indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise. It is particularly useful for patients inadequately controlled on their maximally tolerated dose of Metformin alone or those already on separate tablets of Empagliflozin and Metformin. The recommended dosage is typically twice daily with meals to minimize gastrointestinal side effects, with the maximum daily doses being 25 mg of Empagliflozin and 2000 mg of Metformin. Patients with an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m² should not use this combination. Common side effects include urinary tract infections, genital infections, nausea, and diarrhea. As with any medication, it is essential to consult a healthcare professional before starting treatment to ensure it is appropriate for your specific medical condition.
.png)
.jpeg)
.png)
.webp)
.png)
.jpeg)
.jpeg)
.webp)
.webp)
Change Language